| 1 |
34838486 | [Angiogenesis inhibitors: mechanism of action and nephrotoxicity]. | 2022 Feb |
1 |
| 2 |
35456602 | Dual-Functional Polymeric Micelles Co-Loaded with Antineoplastic Drugs and Tyrosine Kinase Inhibitor for Combination Therapy in Colorectal Cancer. | 2022 Mar 31 |
1 |
| 3 |
35562342 | DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma. | 2022 May 13 |
1 |
| 4 |
33812180 | Acute sunitinib neurotoxicity. | 2021 |
2 |
| 5 |
33863648 | Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. | 2021 Aug |
1 |
| 6 |
34763724 | Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report. | 2021 Nov 12 |
1 |
| 7 |
31744648 | Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience. | 2020 Jan - Feb |
1 |
| 8 |
31866228 | Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA. | 2020 Apr |
2 |
| 9 |
32232883 | Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. | 2020 May |
1 |
| 10 |
32661119 | Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. | 2020 Jul |
1 |
| 11 |
30640790 | Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature. | 2019 Apr |
1 |
| 12 |
30648632 | The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. | 2019 Feb |
1 |
| 13 |
30722031 | Overview of current and future systemic therapy for metastatic renal cell carcinoma. | 2019 May 1 |
1 |
| 14 |
31035254 | EGF and IGF1 affect sunitinib activity in BP-NEN: new putative targets beyond VEGFR? | 2019 Jun 1 |
1 |
| 15 |
31268155 | Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment. | 2019 Aug |
2 |
| 16 |
31443471 | The Changing Therapeutic Landscape of Metastatic Renal Cancer. | 2019 Aug 22 |
2 |
| 17 |
31471309 | Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. | 2019 Oct 15 |
1 |
| 18 |
28676023 | Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma. | 2018 Jan 26 |
2 |
| 19 |
29095068 | Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. | 2018 Apr |
2 |
| 20 |
29289530 | A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs. | 2018 Jan |
1 |
| 21 |
29345296 | Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. | 2018 Feb |
2 |
| 22 |
29532881 | VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells. | 2018 Apr |
1 |
| 23 |
29563634 | The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma. | 2018 May |
1 |
| 24 |
29854307 | Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells. | 2018 Apr 27 |
1 |
| 25 |
30109169 | Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells. | 2018 |
1 |
| 26 |
30168120 | Advances in the Treatment of Metastatic Renal Cell Carcinoma. | 2018 |
2 |
| 27 |
30202791 | Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. | 2018 |
1 |
| 28 |
30369518 | Interleukin-6 induces drug resistance in renal cell carcinoma. | 2018 Dec 8 |
1 |
| 29 |
30428867 | Spontaneous regression of adrenal metastasis from renal cell carcinoma after sunitinib withdrawal: case report and literature review. | 2018 Nov 14 |
2 |
| 30 |
30636586 | miRNA Targeting Angiogenesis as a Potential Therapeutic Approach in the Treatment of Colorectal Cancers. | 2018 |
1 |
| 31 |
27395374 | Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. | 2017 Mar |
2 |
| 32 |
27896475 | An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. | 2017 Feb |
1 |
| 33 |
28167241 | The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic Profiles. | 2017 Apr |
1 |
| 34 |
28276433 | Renal cell carcinoma. | 2017 Mar 9 |
2 |
| 35 |
28330808 | Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. | 2017 Oct |
1 |
| 36 |
28452850 | Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells. | 2017 Jun |
1 |
| 37 |
28478454 | Vascular Endothelial Growth Factor Augments Arginine Transport and Nitric Oxide Generation via a KDR Receptor Signaling Pathway. | 2017 |
1 |
| 38 |
28670632 | Systemic Sunitinib Malate Treatment for Advanced Juxtapapillary Retinal Hemangioblastomas Associated with von Hippel-Lindau Disease. | 2017 May-Jun |
1 |
| 39 |
28672196 | Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. | 2017 Aug |
1 |
| 40 |
28903416 | Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. | 2017 Aug 15 |
1 |
| 41 |
28978162 | Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. | 2017 Sep 15 |
1 |
| 42 |
29359059 | Sunitinib-Induced Acute Interstitial Nephritis in a Thrombocytopenic Renal Cell Cancer Patient. | 2017 |
2 |
| 43 |
26540173 | Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. | 2016 Feb 1 |
1 |
| 44 |
26617188 | Clinical management of metastatic kidney cancer: the role of new molecular drugs. | 2016 Jan |
1 |
| 45 |
26733173 | The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells. | 2016 Jul |
1 |
| 46 |
26755746 | The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia. | 2016 Oct |
1 |
| 47 |
26832420 | [Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management]. | 2016 Mar |
1 |
| 48 |
26893877 | Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer. | 2016 Feb |
1 |
| 49 |
26923603 | P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. | 2016 Mar 8 |
1 |
| 50 |
27034725 | The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. | 2016 Apr |
2 |